All media enquiries:

Announcing Positive Phase 2 Results as First Digital Therapeutic to Improve Memory, Cognition, Functional Abilities and Reduce Brain Atrophy in Alzheimer’s Disease

March 9, 2021

Cognito Therapeutics to Announce New Clinical Data Evaluating Gamma Frequency Neuromodulation to Treat Alzheimer’s Disease at 2021 AD/PD Virtual Conference

March 2, 2021

Cognito Therapeutics Receives FDA Breakthrough Device Designation for Next-Generation Digital Therapeutic in Alzheimer’s Disease

January 12, 2021

Brent Vaughan Appointed CEO of Cognito Therapeutics

October 12, 2020

Announcing the Appointment of Mihály Hajós as Chief Scientific Officer

June 26, 2019